NexImmune, Inc.
NEXI · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2,121 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $75 | $115 | $229 | $266 |
| Gross Profit | -$75 | -$115 | $1,892 | -$266 |
| % Margin | – | – | 89.2% | – |
| R&D Expenses | $647 | $629 | $1,247 | $6,006 |
| G&A Expenses | $2,082,494 | $2,013 | $2,405 | $3,990 |
| SG&A Expenses | $2,082 | $2,013 | -$685 | $3,990 |
| Sales & Mktg Exp. | -$2,080,412 | $0 | $0 | $0 |
| Other Operating Expenses | $779 | $0 | $0 | -$13 |
| Operating Expenses | $3,509 | $2,643 | $562 | $9,996 |
| Operating Income | -$3,509 | -$2,757 | -$3,692 | -$9,996 |
| % Margin | – | – | -174.1% | – |
| Other Income/Exp. Net | $1,183 | -$320 | -$1,666 | -$1,964 |
| Pre-Tax Income | -$2,327 | -$3,077 | -$5,359 | -$9,854 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,327 | -$3,077 | -$5,359 | -$9,854 |
| % Margin | – | – | -252.7% | – |
| EPS | -1.69 | -2.46 | -5.03 | -9.4 |
| % Growth | 31.3% | 51.1% | 46.5% | – |
| EPS Diluted | -1.69 | -2.46 | -5.03 | -9.4 |
| Weighted Avg Shares Out | 1,380 | 1,250 | 1,066 | 1,048 |
| Weighted Avg Shares Out Dil | 1,380 | 1,250 | 1,066 | 1,048 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $15 | $45 | $155 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $75 | $115 | $229 | $266 |
| EBITDA | -$2,654 | -$2,643 | -$5,130 | -$7,625 |
| % Margin | – | – | -241.9% | – |